NASDAQ:LBPS - 4D pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.50
  • Forecasted Upside: 426.69 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.12
▼ -0.07 (-0.97%)

This chart shows the closing price for LBPS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 4D pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LBPS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LBPS

Analyst Price Target is $37.50
▲ +426.69% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for 4D pharma in the last 3 months. The average price target is $37.50, with a high forecast of $40.00 and a low forecast of $35.00. The average price target represents a 426.69% upside from the last price of $7.12.

This chart shows the closing price for LBPS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in 4D pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/7/2021Chardan CapitalReiterated RatingBuy$40.00Medium
5/13/2021LADENBURG THALM/SH SHInitiated CoverageBuy$35.00High
4/7/2021Chardan CapitalReiterated RatingBuyMedium
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
4D pharma logo
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
Read More

Today's Range

Now: $7.12
Low: $7.00
High: $7.34

50 Day Range

MA: $8.90
Low: $6.93
High: $10.10

52 Week Range

Now: $7.12
Low: $6.93
High: $15.50

Volume

21,500 shs

Average Volume

22,114 shs

Market Capitalization

$117.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.04

Frequently Asked Questions

What sell-side analysts currently cover shares of 4D pharma?

The following Wall Street research analysts have issued research reports on 4D pharma in the last year: Chardan Capital, LADENBURG THALM/SH SH, and Zacks Investment Research.
View the latest analyst ratings for LBPS.

What is the current price target for 4D pharma?

2 Wall Street analysts have set twelve-month price targets for 4D pharma in the last year. Their average twelve-month price target is $37.50, suggesting a possible upside of 426.7%. Chardan Capital has the highest price target set, predicting LBPS will reach $40.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $35.00 for 4D pharma in the next year.
View the latest price targets for LBPS.

What is the current consensus analyst rating for 4D pharma?

4D pharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LBPS will outperform the market and that investors should add to their positions of 4D pharma.
View the latest ratings for LBPS.

How do I contact 4D pharma's investor relations team?

4D pharma's physical mailing address is 9 BOND COURT 5TH FLOOR, LEEDS X0, LS1 2JZ. The company's listed phone number is 44-0-11-3895-0130 and its investor relations email address is [email protected] The official website for 4D pharma is www.4dpharmaplc.com.